share_log

Exicure | DEF 14A: Definitive information statements

Exicure | DEF 14A: Definitive information statements

Exicure | DEF 14A：股東委託書決議
美股sec公告 ·  06/11 12:17
Moomoo AI 已提取核心訊息
Exicure, Inc., a biotechnology company specializing in gene regulatory and immunotherapeutic drugs, announced the scheduling of its combined 2024 and 2023 Annual Meeting of Stockholders to be held virtually on June 28, 2024. The meeting will address the election of Class III and Class I directors, ratification of the company's independent auditor, advisory approval of executive compensation, and the frequency of such compensation reviews. The meeting will also cover any additional business that may arise. The record date for determining stockholder eligibility to vote at the meeting is set for May 15, 2024. Stockholders will be able to attend the meeting online, submit questions, and vote their shares electronically. The company did not hold an Annual Meeting in 2023, making this a combined meeting for both years. Proxy materials, including the Proxy Statement and the 2023 Annual Report, are available online for stockholders.
Exicure, Inc., a biotechnology company specializing in gene regulatory and immunotherapeutic drugs, announced the scheduling of its combined 2024 and 2023 Annual Meeting of Stockholders to be held virtually on June 28, 2024. The meeting will address the election of Class III and Class I directors, ratification of the company's independent auditor, advisory approval of executive compensation, and the frequency of such compensation reviews. The meeting will also cover any additional business that may arise. The record date for determining stockholder eligibility to vote at the meeting is set for May 15, 2024. Stockholders will be able to attend the meeting online, submit questions, and vote their shares electronically. The company did not hold an Annual Meeting in 2023, making this a combined meeting for both years. Proxy materials, including the Proxy Statement and the 2023 Annual Report, are available online for stockholders.
生物技術公司Exicure，專門從事基因調節和免疫治療藥物，宣佈將於2024年6月28日通過虛擬方式，召開2024和2023年股東年度聯席會議。會議將討論選舉第三類和第一類董事，確認公司獨立核數師，對執行薪酬的諮詢批准，以及此類薪酬審查的頻率。會議還將涵蓋可能出現的任何其他業務。確定股東有投票權的記錄日期設定爲2024年5月15日。股東將能夠在線參加會議，提交問題並電子投票。該公司未在2023年召開股東年度聯席會議，因此將會是2023和2024年的聯席會議。股東的代理材料，包括代理聲明和2023年年度報告，均可在線獲取。
生物技術公司Exicure，專門從事基因調節和免疫治療藥物，宣佈將於2024年6月28日通過虛擬方式，召開2024和2023年股東年度聯席會議。會議將討論選舉第三類和第一類董事，確認公司獨立核數師，對執行薪酬的諮詢批准，以及此類薪酬審查的頻率。會議還將涵蓋可能出現的任何其他業務。確定股東有投票權的記錄日期設定爲2024年5月15日。股東將能夠在線參加會議，提交問題並電子投票。該公司未在2023年召開股東年度聯席會議，因此將會是2023和2024年的聯席會議。股東的代理材料，包括代理聲明和2023年年度報告，均可在線獲取。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息